title: Treatment of MRSA soft tissue infections: an overview.
abstract: MRSA is becoming increasingly common worldwide. With the emergence of new highly spreadable strains (community associated or CA-MRSA) novel presentation skin and soft tissue infections (SSTI) are being seen. Recurrent SSTI, including folliculitis, furunculosis and abscesses account for an increasing proportion of SSTI seen in the emergency department. Empirical antimicrobial management choices can be difficult, but clues to the nature of the MRSA may be gleaned from the history and clinical presentation. More severe SSTI due to necrotising fasciitis and purpura fulminans are emerging and warrant the broadest possible empirical Gram-positive cover, ideally with antimicrobials that stop exotoxin production, and sometimes intravenous immunoglobulin to neutralise exotoxins already produced.
authors.affiliation: Department of Microbiology, Royal Devon & Exeter NHS Foundation Trust, Barrack Road, Exeter EX2 5DW, UK. marina.morgan@rdeft.nhs.uk
authors.forename: M
authors.initials: M
authors.lastname: Morgan
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001427:Bacterial Toxins / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy; D003657:Decision Making; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D005098:Exotoxins / Q000627:therapeutic use; D019115:Fasciitis, Necrotizing / Q000188:drug therapy; D006801:Humans; D007956:Leukocidins / Q000627:therapeutic use; D055624:Methicillin-Resistant Staphylococcus aureus; D018461:Soft Tissue Infections / Q000188:drug therapy*; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D005098:Exotoxins; D007956:Leukocidins; C078284:Panton-Valentine leukocidin